Actively Recruiting
Evaluating Doravirine Combined Therapy for Rapid Start of HIV-1 Treatment in Adults Without Prior Antiretroviral Use
Led by Fundación Huésped · Updated on 2026-09-23
100
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the antiviral activity and safety of a combined medication containing doravirine, lamivudine, and tenofovir disoproxil DOR3TCTDF for rapid initiation of highly active antiretroviral therapy HAART in adults diagnosed with HIV-1 infection who have not previously received antiretroviral treatment. This phase IV, multicenter, non-randomized, open-label study aims to understand how well this treatment works and how safe it is over 48 weeks. Participants will take one oral tablet daily containing doravirine 100 mg, lamivudine 300 mg, and tenofovir disoproxil 245 mg for up to 48 weeks. The study focuses on rapid initiation of therapy soon after diagnosis. The treatment group consists of a single arm receiving this combination therapy without a placebo or comparison group. Throughout the study, participants will be regularly monitored for viral load suppression, immune response through CD4 and CD8 T-cell counts, development of drug resistance, changes in weight, body mass index, and lipid profiles at weeks 24 and 48. Safety and tolerability will also be evaluated. The primary outcome is the antiviral activity at week 48. Participants are expected to attend scheduled visits for assessments and laboratory tests over the 48-week period.
CONDITIONS
Brief Title
Efficacy and Safety of Doravirine in the Rapid Initiation
Research Team
P
Pedro E Cahn, MD
M
María I Figueroa, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here